Drug Profile
Research programme: cancer radiotherapeutics - Algeta/Avipep
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Algeta; Avipep
- Class Drug conjugates; Immunoglobulin Fv fragments; Proteins; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in Australia (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in Norway (Parenteral)
- 06 Mar 2014 Algeta has been acquired by Bayer